Return to Gastroenterology Alert Section
Data from University of Gottingen advance knowledge in colon cancer
November 26th, 2007
2007 NOV 26 -- According to a study from Germany, "We tested whether adjuvant radioimmunotherapy (RAIT) given after R0 resection of liver metastases (LM) of colorectal cancer is safe and can improve survival. Resection of LM from colorectal cancer is the standard of care in this setting, yet two thirds will eventually relapse, and adjuvant systemic chemotherapy has failed to improve survival Twenty-three patients who underwent R0 resection for LM of colorectal cancer received a dose of 40 to 60 mCi/m(2) I-131-labetuzumab, a humanized monoclonal antibody against carcinoembryonic antigen." "Safety (n = 23), disease-free survival, and overall survival (n = 19) were analyzed, and efficacy was then compared retrospectively with a similar contemporaneous group of control patients (n = 19) treated at the same institution during the same time period but without RAIT At a median follow-up of 91 months (95% confidence interval [CI], 68.0 months to infinity), the median overall survival for RAIT patients was 58.0 months (95% CI, 55.0 months to infinity), versus 31.0 months (95% CI, 26.0 months to infinity) at a 51-month median follow-up for the controls (P = .032). The median disease-free survival for RAIT patients was 18.0 months (95% CI, 11.0-31.0 months), versus 12.0 months (95% CI, 6.5-27.0 months) for the controls (P = .565). Corresponding survival rates (Kaplan-Meier analyses) were estimated to be 94.7% at 1 year, 78.9% at 2 years, 68.4% at 3 years, and 42.1% at 5 years with RAIT and 94.7%, 68.4%, 36.8%, and 15.8%, respectively, for the controls. RAIT was beneficial independently of bilobar involvement, size and number of LM, or resection margins," wrote T. Liersch and colleagues, University of Gottingen. The researchers concluded: "Transient myelosuppression was the principal adverse effect This first evidence of a promising survival advantage of adjuvant RAIT after long-term follow-up of colorectal cancer patients given salvage resection of LM warrants confirmation in a prospective randomized trial." Liersch and colleagues published their study in Annals of Surgical Oncology (Update of carcinoembryonic antigen radioimmunotherapy with (131)supercript stopI-Labetuzumab after salvage resection of colorectal liver metastases: Comparison of outcome to a contemporaneous control group. Annals of Surgical Oncology, 2007;14(9):2577-2590). For more information, contact D.M. Goldenberg, University of Gottingen, Dept. of General Surgery, D-3400 Gottingen, Germany. Publisher contact information for the journal Annals of Surgical Oncology is: Springer, 233 Spring Street, New York, NY 10013, USA. Keywords: Germany, Colon Cancer, Colon Carcinoma, Oncology, University of Gottingen. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2007, Clinical Oncology Week via NewsRx.com.
Return to Gastroenterology Alert Section
|
